CAR T-Cell Therapy Market Expected to Surpass USD 11 Billion by 2030 with 23.8% CAGR

Richmond, United States, 2024-Apr-04 — /EPR Network/ —

The CAR T-Cell Therapy Market size is estimated to increase from USD 8.2 billion in 2022 to USD 11.2 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 23.8% during the forecast period from 2023 to 2030.

CAR T-cell therapy, a revolutionary approach in cancer treatment, has emerged as a beacon of hope for patients facing refractory malignancies. This blog navigates through the dynamic landscape of the CAR T-Cell Therapy Market, shedding light on its transformative capabilities, ongoing innovations, and future outlook.

Request free Sample:

Major players CAR T-Cell Therapy Market include:

  • Pfizer, Inc.
  • Cellectis
  • Caribou Biosciences, Inc.
  • Celyad Oncology
  • Merck & Co., Inc.
  • Celgene Corporation
  • Juno Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • Bluebird Bio, Inc.
  • Gilead Sciences, Inc. (Kite Pharma Inc.)
  • Cartesian Therapeutics, Inc.
  • Bristol-Myers Squibb
  • Miltenyi Biotech
  • Autolus Therapeutics
  • Novartis AG
  • Other

Market Trends and Drivers:

  • Escalating Cancer Incidence: The rising prevalence of cancer worldwide, coupled with the limitations of conventional treatments in some cases, underscores the demand for novel therapies like CAR T-cell therapy, offering promising avenues for cancer treatment.
  • Technological Advancements: Rapid progress in biotechnology, gene editing techniques, and cell therapy manufacturing processes has propelled the development and commercialization of CAR T-cell therapies, expanding treatment options for patients with various hematological malignancies and solid tumors.
  • Regulatory Support: Regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) validate the clinical efficacy and safety of CAR T-cell therapies, fostering market growth and adoption.
  • Personalized Treatment Approach: CAR T-cell therapy exemplifies the paradigm of personalized medicine, delivering tailored treatments based on individual patient characteristics and tumor molecular profiles, potentially enhancing treatment outcomes and minimizing adverse effects.

Request for Discount :

Major Classifications are as follows:

  • By Drug Type:
    • Abecma (idecabtagene vicleucel)
    • Breyanzi (lisocabtagene maraleucel)
    • Carvykti (ciltacabtagene autoleucel)
    • Kymriah (tisagenlecleucel)
    • Tecartus (brexucabtagene autoleucel)
    • Yescarta (axicabtagene ciloleucel)
    • Others
  • By Indication:
    • Lymphoma
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia (CLL)
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma (MM)
    • Others
  • By Target Antigen:
    • CD 19
    • CD 20
    • GD2
    • CD22
    • CD30
    • CD33
    • HER1
    • HER2
    • Others
  • By End user:
    • Hospitals
    • Cancer Treatment Centers
    • Others
  • By Region
    • North America
      • US
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Rest of Asia Pacific
    • Middle East & Africa
      • UAE
      • Saudi Arabia
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Core Therapies and Innovations: CAR T-cell therapy encompasses diverse treatments targeting various cancers, including:

  • Kymriah (Tisagenlecleucel): Novartis’ CAR T-cell therapy approved for certain leukemias and lymphomas, pioneering the commercialization of CAR T-cell therapies.
  • Yescarta (Axicabtagene Ciloleucel): Gilead Sciences’ CAR T-cell therapy indicated for specific lymphomas, demonstrating significant clinical efficacy and durable responses in clinical trials.
  • Breyanzi (Lisocabtagene Maraleucel): Bristol Myers Squibb’s CAR T-cell therapy approved for certain lymphomas, offering an alternative treatment option with improved manufacturing efficiency and patient accessibility.
  • Ide-cel (Abecma): Bristol Myers Squibb’s CAR T-cell therapy approved for multiple myeloma, marking a milestone in CAR T-cell therapy development for solid tumors.
  • BCMA-targeted CAR T-cell therapies: Various companies are developing CAR T-cell therapies targeting B-cell maturation antigen (BCMA) for multiple myeloma treatment.

Buy Now market report:


CAR T-cell therapy represents a revolutionary breakthrough in cancer treatment, offering renewed hope for patients facing challenging malignancies. By harnessing the immune system’s power to target and eliminate cancer cells, CAR T-cell therapies have the potential to redefine cancer care and enhance patient outcomes. As the CAR T-Cell Therapy Market evolves, collaboration between industry stakeholders, researchers, and healthcare providers will be instrumental in driving innovation, expanding access, and realizing the full potential of this transformative therapy in the battle against cancer.

 Contact Us:
1248 CarMia Way Richmond,
VA 23235, United States.
Phone: +1 510-730-3200

Matched content

Editor’s pick

Express Press Release Distribution